Your Article Summary
Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection
Expert Opinion in Pharmacotherapy, 07/01/09
Iacobellis A et al. - Treatment is only recommended for a well-compensated liver cirrhosis, whereas antiviral therapy is commonly not implemented in cirrhotics with signs of liver decompensation, over the concern that the use of peginterferon and ribavirin might expose patients to severe treatment-related side effects. This review focuses on data available to support both efficacy and safety of antiviral therapy in both compensated and decompensated cirrhotic patients.
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Chloroquine reduces arylsulphatase B activity and increases chondroitin 4-sulphate: implications for mechanisms of action and resistance
Malaria Journal, 12/18/09
Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infection: a meta-analysis
Current Medical Research and Opinion, 12/17/09
Artesunate plus amodiaquine combination therapy: reviewing the evidence
Drug Development Research, 12/17/09
Today in Stomach/GI...keeping you current
Receive free subspecialty "5-minute updates" via email
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B
Journal of Viral Hepatitis, 12/17/09
Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy
Langenbeck's Archives of Surgery, 12/17/09
The efficacy and safety of telaprevir ? a new protease inhibitor against hepatitis C virus
Expert Opinion on Investigational Drugs, 12/16/09

See Latest Articles